Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemothera...
Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Chemotherapy is the mainstay systemic therapy for PDAC, and chemoresistance is a major clinical problem leading to therapeutic failure. This study aimed to identify key differences in gene expression profile in tumors from chemoresponsive and chemoresistant p...
Alternative Titles
Full title
Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e90fdec124084c0493ac5c88c8aabda8
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e90fdec124084c0493ac5c88c8aabda8
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.6411
